Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836

Clinical trial NCT06582277 · COMPLETED

Trial details

NCT number: NCT06582277
Sponsor: Osivax
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Vaccine-Preventable Diseases Influenza

Start date: 2024-10-22
Primary completion: 2025-06-02
Enrollment: 117

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.